Fat jab works on six-year-olds, trial finds
Novo's Wegovy injections reduced BMI by 17.4% in 6-12-year-olds, with 40% no longer obese. Trial involved 165 children, 80% on semaglutide. Side effects included nausea, diarrhea. Novo aims to address childhood obesity, partnering with Unicef. Separately, Eli Lilly's Zepbound reduced BMI by 21.4% in 12-18-year-olds.
How this was made

The 30-second read
Why it matters
If regulators accept pediatric efficacy and safety, it can expand addressable markets and strengthen competitive positioning for GLP-1 obesity therapies. The trial’s specific BMI reductions and the absence of puberty-related safety concerns are the main decision-relevant details.
Market read
Pediatric obesity efficacy and safety read-through can shift expectations for future label expansion and competitive dynamics between semaglutide and tirzepatide franchises.
What to watch
Key missing items for trading are durability beyond the follow-up window, discontinuation effects, and whether regulators will require additional endpoints or longer safety monitoring in younger children.
Background
The article describes new clinical trial results for GLP-1 obesity drugs in children, focusing on Novo’s Wegovy (semaglutide) and a separate trial for Eli Lilly’s Zepbound (tirzepatide).
Ticker impact
Novo reports a trial in 6-12 year olds where Wegovy reduced BMI by 17.4% after 68 weeks and 40% were no longer obese.
Likely upward bias as investors price in expanded pediatric market opportunity and reduced perceived safety risk.
The article is centered on Novo’s Wegovy pediatric trial results with specific efficacy and safety findings, which are material for future commercialization, though the piece does not mention regulatory approval timing.
Eli Lilly’s Zepbound is described as helping 12-18 year olds reduce BMI by an average 21.4% over 72 weeks in a separate trial.
Likely supportive reaction as the market weighs competitive read-through versus Novo’s pediatric data.
The article mentions Lilly’s trial results but provides less detail than Novo’s, and it does not state regulatory outcomes or direct commercial implications.
Market effects
Reinforces the GLP-1 obesity drug class narrative for earlier-age treatment, potentially increasing competitive intensity and investor focus on pediatric safety and efficacy.
Primarily impacts US and EU obesity-drug expectations, with UK/EU label context referenced for Novo.
Could accelerate global demand forecasts for semaglutide and tirzepatide in pediatric obesity markets.
Counterpoint
Efficacy in a trial may not translate into durable real-world outcomes, adherence, and long-term safety, so near-term pricing may overreact to interim follow-up.
Key entities
- companyNovo Nordisk
Reports Wegovy trial results in children aged 6-12, including BMI reduction and obesity reclassification rates.
- drugWegovy
Semaglutide GLP-1 obesity injection; trial data presented for ages 6-12.
- companyEli Lilly
Reports separate Zepbound trial results in ages 12-18.
- drugZepbound
Tirzepatide weight-loss drug; trial data presented for ages 12-18.


